PMID- 22264640
OWN - NLM
STAT- MEDLINE
DCOM- 20130301
LR  - 20211203
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 40
IP  - 5
DP  - 2012 Sep-Oct
TI  - Omalizumab beyond asthma.
PG  - 306-15
LID - S0301-0546(11)00360-0 [pii]
LID - 10.1016/j.aller.2011.09.011 [doi]
AB  - INTRODUCTION: Omalizumab has been demonstrated to be a successful therapy in the 
      management of asthma through reduction of patient's symptoms and use of inhaled 
      corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) 
      blockage and other secondary mechanisms resulting from this blockage. Because 
      other diseases have an important IgE mediation in their physiopathology, the 
      question arises as to if omalizumab would be useful in the treatment of other 
      IgE-mediated diseases. OBJECTIVE: We present an overview of the experimental 
      studies and clinical reports evaluating the use of omalizumab in diseases 
      different to asthma including atopic dermatitis, urticaria, eosinophilic 
      gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera 
      venom allergy, and other IgE diseases. METHODS: We reviewed the literature using 
      PUBMED, EMBASE, and LILACS for publications which used omalizumab in the 
      treatment of patients with allergic diseases or any other diseases. Complete 
      articles published in English, Spanish or Portuguese were included. CONCLUSION: 
      There is not enough evidence to support the regular use of omalizumab in IgE 
      diseases other than asthma. However, some experimental and clinical 
      investigations indicate that omalizumab could be a therapeutic option in several 
      allergic diseases like atopic dermatitis, urticaria, and eosinophilic 
      gastrointestinal disorders. More control studies are needed in each IgE disease 
      to evaluate the efficacy and safety of omalizumab in IgE mediated diseases.
CI  - Copyright (c) 2011 SEICAP. Published by Elsevier Espana. All rights reserved.
FAU - Sanchez, J
AU  - Sanchez J
AD  - Group of Clinical and Experimental Allergology (GACE), Medellin, Colombia.
FAU - Ramirez, R
AU  - Ramirez R
FAU - Diez, S
AU  - Diez S
FAU - Sus, S
AU  - Sus S
FAU - Echenique, A
AU  - Echenique A
FAU - Olivares, M
AU  - Olivares M
FAU - Cardona, R
AU  - Cardona R
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120120
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, IgE)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Asthma/*drug therapy/immunology
MH  - Cell Degranulation/drug effects
MH  - Humans
MH  - Hypersensitivity/*drug therapy/immunology
MH  - Immunoglobulin E/*immunology
MH  - Immunosuppression Therapy/methods
MH  - Lymphocyte Activation/drug effects
MH  - Omalizumab
MH  - Receptors, IgE/immunology
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2012/01/24 06:00
MHDA- 2013/03/02 06:00
CRDT- 2012/01/24 06:00
PHST- 2011/08/13 00:00 [received]
PHST- 2011/09/22 00:00 [accepted]
PHST- 2012/01/24 06:00 [entrez]
PHST- 2012/01/24 06:00 [pubmed]
PHST- 2013/03/02 06:00 [medline]
AID - S0301-0546(11)00360-0 [pii]
AID - 10.1016/j.aller.2011.09.011 [doi]
PST - ppublish
SO  - Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 
      10.1016/j.aller.2011.09.011. Epub 2012 Jan 20.